dc.contributor.author | Heffron, Renee | |
dc.contributor.author | Nelly, Mugo | |
dc.contributor.author | Edwin, Were | |
dc.contributor.author | Kiarie, James | |
dc.contributor.author | Bukusi, Elizabeth A | |
dc.contributor.author | Mujugira, Andrew | |
dc.contributor.author | Frenkel, Lisa | |
dc.contributor.author | Donnell, Deborah | |
dc.contributor.author | Ronald, Allan | |
dc.contributor.author | Celum, Connie | |
dc.contributor.author | Baeten, Jared M | |
dc.date.accessioned | 2014-12-30T09:22:49Z | |
dc.date.available | 2014-12-30T09:22:49Z | |
dc.date.issued | 2014-11 | |
dc.identifier.citation | AIDS. Nov 28, 2014; 28(18): 2771–2776 | en_US |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266161/ | |
dc.identifier.uri | http://hdl.handle.net/11295/78500 | |
dc.description.abstract | Objective
To evaluate pre-exposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1 infected partners use DMPA.
Design
Secondary analysis of data from a randomized placebo-controlled trial of daily oral tenofovir and emtricitabine/tenofovir PrEP among heterosexual Kenyan and Ugandan HIV-1 serodiscordant couples
Methods
PrEP efficacy for HIV-1 prevention was compared among HIV-1 uninfected women using DMPA versus no hormonal contraception and among HIV-1 uninfected men whose HIV-1 infected female partners used DMPA versus no hormonal contraception.
Results
Of 4747 HIV-1 serodiscordant couples, 901 HIV-1 uninfected women used DMPA at some point during follow-up, 1422 HIV-1 uninfected women used no hormonal contraception, 1568 HIV-1 uninfected men had female partners who used DMPA, and 2626 men had female partners who used no hormonal contraception. PrEP efficacy estimates for HIV-1 prevention, compared to placebo, were similar among women using DMPA and those using no hormonal contraception (64.7% and 75.5%, adjusted interaction p=0.65). Similarly, for men whose female partners used DMPA, PrEP efficacy did not differ from men whose partners used no hormonal contraception (90.0% versus 81.7%, adjusted interaction p=0.52).
Conclusions
PrEP is efficacious for HIV-1 prevention among women using DMPA and men whose partners use DMPA, suggesting PrEP could mitigate the potential increased HIV-1 acquisition and transmission risks that have been associated with DMPA use. Women at risk for HIV-1 choosing DMPA could maintain this contraceptive method and add PrEP to achieve prevention of unintended pregnancy and HIV-1. | en_US |
dc.language.iso | en | en_US |
dc.publisher | University of Nairobi | en_US |
dc.subject | HIV-1 prevention, pre-exposure prophylaxis efficacy, hormonal contraception, DMPA | en_US |
dc.title | PrEP is Efficacious for HIV-1 prevention among Women using DMPA for Contraception | en_US |
dc.type | Article | en_US |
dc.type.material | en | en_US |